Chapter 46 END-STAGE LIVER DISEASE
INTRODUCTION
End-stage liver disease is also known as decompensated liver disease. It develops in patients with underlying cirrhosis due to a wide variety of causes, including chronic hepatitis C, chronic hepatitis B, alcoholic liver disease, non-alcoholic fatty disease, autoimmune liver diseases (autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis) and genetic or metabolic liver diseases (alpha1-antitrypsin deficiency, genetic haemochromatosis, Wilson’s disease). Despite the wide aetiological processes involved in the development of cirrhosis, the manifestations of end-stage liver disease are common to all, and are consequent to the combination of portal hypertension and hepatic synthetic failure (Table 46.1). Extrahepatic manifestations of end-stage liver disease include hepatopulmonary syndrome and portopulmonary hypertension. In addition, the presence of cirrhosis predisposes to hepatocellular carcinoma (HCC), bone disease and malnutrition.
Complications of portal hypertension and portosystemic shunting |
Consequences of hepatic synthetic failure |
ASSESSMENT
History
The essential elements of history taking for patients with end-stage liver disease (Figure 46.1) include:
Physical examination
Assessment of patient with end-stage liver disease (Figure 46.1) should include examination for:
Laboratory evaluation
In addition to the investigations listed, other specific investigations will be required to determine the cause of liver disease (Figure 46.1).